Targeted attack on lingering leukemia cells
NCT ID NCT05456698
Summary
This study is testing whether a targeted drug called inotuzumab ozogamicin can eliminate trace amounts of cancer cells that remain in adults with a type of acute lymphocytic leukemia (ALL) after their first round of chemotherapy. The goal is to see if this treatment can help prevent the cancer from returning. The trial will enroll about 31 adults at a single center in China to measure how well the drug works and monitor its safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.